Hunan Jingfeng Pharmaceutical Co EBIT per osake

Mitä Hunan Jingfeng Pharmaceutical Co tekee? Hunan Jingfeng Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical and biological drugs. Its main product categories include cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs, and anti-infective drugs. The company distributes these products domestically and also engages in commodity import and export trading, business management and consulting, and medical technology consulting services. Sales are primarily directed at the domestic market with no mention of international distribution channels. The firm's revenue streams are derived from pharmaceutical sales, particularly in cardiovascular, oncology, and infectious disease treatments, alongside ancillary services such as medical technology consulting. The domestic market remains the sole focus for product distribution, with no indication of export-oriented sales. The company's operations are centered on drug manufacturing and related consulting services, targeting healthcare providers and domestic consumers through established distribution networks. Hunan Jingfeng Pharmaceutical's business model emphasizes product diversity across multiple therapeutic areas, including cardiovascular, oncology, and infectious diseases. The company's revenue is driven by both direct pharmaceutical sales and ancillary consulting services, with all activities confined to the domestic market. The absence of international operations or export-focused strategies is consistent with the business description provided. Hunan Jingfeng Pharmaceutical Co on yksi Eurpooliin suosituimmista yhtiöistä.